Abstract
Malignant gliomas are characterized by an extensive vasculature. The most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF), is therefore a therapeutic target for anti-angiogenic therapy. This chapter focuses on different functional characteristics of VEGF and its receptors in the angiogenesis process. Furthermore, the effects of decreasing or blocking VEGF using the humanized monoclonal antibody to VEGF, bevacizumab (Avastin), are discussed. The possible mechanisms of activity of this agent, as well as potential problems with this drug are also discussed.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Current Radiopharmaceuticals
Recent Patents on Anti-Cancer Drug Discovery
Current Medicinal Chemistry - Anti-Cancer Agents
Current Cancer Therapy Reviews
Clinical Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents